Skip to content

Bioventus BVS Free cash flow

Free cash flow at other companies

Stryker logo
StrykerSYK
$415M+227%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
Artivion logo
ArtivionAORT
-$6.85M+66.7%
Avanos Medical logo
Avanos MedicalAVNS
-$16.6M-187%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
Globus Medical logo
Globus MedicalGMED

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Calculated from Bioventus’s reported figures.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's free cash flow?
Bioventus (BVS) reported free cash flow of $8.36M in Q1 2026.
How has Bioventus's free cash flow changed year-over-year?
Bioventus's free cash flow increased by 141.5% year-over-year, from -$20.16M to $8.36M.
What is the long-term trend for Bioventus's free cash flow?
Over 3 years (2021 to 2025), Bioventus's free cash flow has grown at a 96.7% compound annual growth rate (CAGR), from $9.47M to $72.11M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.